What question did this study set out to answer?

This research aims to evaluate the effects of glatiramer acetate on T-cell responses in multiple sclerosis patients.

Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial examines glatiramer acetate's effects on T-cell responses in multiple sclerosis, indicating potential for autoimmune therapy.

This research aims to evaluate the effects of glatiramer acetate on T-cell responses in multiple sclerosis patients.
Examined effects of glatiramer acetate on antigen-specific T-cell responses in patients with MS and healthy subjects.
Analyzed T-cell proliferation and cytokine secretion profiles after daily injections of glatiramer acetate.
Measured the degree of T-cell degeneracy through responses to peptide libraries.
Daily glatiramer acetate injections significantly reduced T-cell responses in patients with MS.
Patients exhibited increased secretion of IL-5 and IL-13, indicative of Th2 polarization.
Cross-reactive T cells showed a higher level of degeneracy, suggesting complex immune responses.

Duda et al. (2000) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial examines glatiramer acetate's effects on T-cell responses in multiple sclerosis, indicating potential for autoimmune therapy.